Increased DHRS12 expression independently predicts poor survival in patients with high-grade serous ovarian cancer

Future Oncol. 2018 Oct;14(25):2579-2588. doi: 10.2217/fon-2018-0242. Epub 2018 May 22.

Abstract

Aim: To explore the expression profile of some DHRS genes in high-grade serous ovarian cancer (SOVC) and to study their prognostic values.

Patients & methods: A retrospective bioinformatic analysis was performed using data in the Gene Expression Omnibus, the Human Protein Atlas and the Cancer Genome Atlas-Ovarian Cancer.

Results: Increased DHRS12 expression was an independent indicator of poor overall survival (hazard ratio [HR]: 1.265, 95% CI: 1.075-1.488; p = 0.005) and recurrence-free survival (RFS; HR: 2.242, 95%CI: 1.464-3.432; p < 0.001) in patients with high-grade SOVC. DNA deletion was associated with decreased DHRS12 expression, as well as the best overall survival and RFS among the three copy number alteration groups.

Conclusion: DHRS12 might serve as a valuable prognostic biomarker in high-grade SOVC.

Keywords: DHRS12; prognosis; serous ovarian cancer.

MeSH terms

  • Adult
  • Aged
  • Alcohol Oxidoreductases / analysis*
  • Biomarkers, Tumor / analysis
  • Carbonyl Reductase (NADPH)
  • Computational Biology
  • Cystadenocarcinoma, Serous / enzymology
  • Cystadenocarcinoma, Serous / mortality*
  • Cystadenocarcinoma, Serous / pathology
  • Female
  • Humans
  • Middle Aged
  • Nuclear Proteins / analysis*
  • Ovarian Neoplasms / enzymology
  • Ovarian Neoplasms / mortality*
  • Ovarian Neoplasms / pathology
  • Prognosis
  • Retrospective Studies
  • Transcriptome

Substances

  • Biomarkers, Tumor
  • Nuclear Proteins
  • Alcohol Oxidoreductases
  • Carbonyl Reductase (NADPH)
  • DHRS2 protein, human